Predictive factors for tolerability of tetrabenazine in patients with hyperkinetic movement disorders

•Data of hyperkinetic patients were analyzed to identify predictive factors for tolerability of tetrabenazine.•Patients with dystonia were 4.1 times more likely to discontinue tetrabenazine.•Tetrabenazine-induced parkinsonism was 5.0 times more likely in tardive syndromes compared to chorea.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Parkinsonism & related disorders 2020-05, Vol.74, p.36-37
Hauptverfasser:	Sahin, Turgut, Yilmaz, Rezzak, Akbostanci, M. Cenk
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adrenergic Uptake Inhibitors - adverse effects Adult Aged Aged, 80 and over Chorea Chorea - drug therapy Drug-Related Side Effects and Adverse Reactions - epidemiology Dystonia Dystonic Disorders - drug therapy Female Humans Huntington's disease Hyperkinesis - drug therapy Male Middle Aged Movement Disorders - drug therapy Parkinson Disease, Secondary - chemically induced Tardive Dyskinesia - drug therapy Tetrabenazine Tetrabenazine - adverse effects Tic disorders Tic Disorders - drug therapy Turkey - epidemiology Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	•Data of hyperkinetic patients were analyzed to identify predictive factors for tolerability of tetrabenazine.•Patients with dystonia were 4.1 times more likely to discontinue tetrabenazine.•Tetrabenazine-induced parkinsonism was 5.0 times more likely in tardive syndromes compared to chorea.
ISSN:	1353-8020 1873-5126
DOI:	10.1016/j.parkreldis.2020.04.007